Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy
In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells (“TABs”) in melanoma progression and resistance to targeted therapy. This study provides a molecular mechanism that governs the cross-talk between TABs and tumor cells as well as a potential new therapeutic strategy for combating tumors resistant to treatment. The study was published online in Nature Communications.
Advanced melanoma is very difficult to treat because even after initially successful treatment, tumors eventually become resistant to conventional and targeted therapies. It is well established that the tumor microenvironment, or the complex of stroma-derived cells and immune cells surrounding cancer cells, plays a role in melanoma progression and therapy resistance. These study results describe how TABs, which account for up to one third of all immune cells that infiltrate the tumor, can promote tumor heterogeneity and cancer stem cell-like populations that are associated with drug resistance. In immunity against infections, B-cells and their progeny, the plasma cells, produce antibodies that can eliminate the disease. Antibodies can also be produced against cancer cells but are rarely effective to eradicate the cancer.
“Our results point to an important cancer-promoting function of tumor-infiltrating B-cells and elucidate the molecular ‘conversation’ between B-cells and melanoma cells, which eventually favors tumor progression and therapy resistance,” said lead researcher Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Professor and director of The Wistar Institute Melanoma Research Center.
Herlyn, Rajasekharan Somasundaram, Ph.D., Research Assistant Professor in the Molecular and Cellular Oncogenesis Program at Wistar, Stephan N. Wagner, M.D., from the Medical University of Vienna, and colleagues used a co-culture system of melanoma cells and B-cells to evaluate the reciprocal effect of the interaction between these two cell types. By using this approach, they could identify those inflammatory factors produced by B-cells and melanoma cells that were relevant for the interaction and can be used as potential targets for novel therapy. The researchers also analyzed tissue samples from melanoma patients and confirmed the prevalence of TABs in advanced, therapy-resistant tumors tissues. Additionally, these tissues showed increased expression of insulin like growth factor (IGF)-1 and fibroblast growth factor receptor (FGFR)-3, identified as crucial players in the B cell-melanoma cross-talk and potential new therapeutic targets for metastatic melanoma.
Importantly, the study also included a pilot multicenter clinical trial to evaluate the therapeutic potential of B-cell depletion in therapy-resistant advanced melanoma patients using a monoclonal antibody that specifically binds to CD20, a molecule present on the surface of these cells, thereby causing their death.
“Our results describe a novel mechanism of drug resistance in melanoma induced by tumor-infiltrating B-cells,” said Somasundaram, first and one of the corresponding authors of the paper. “This study also provides a clinical basis for developing a novel therapeutic approach for advanced melanoma based on targeting tumor infiltrating B-cells.”
This work was supported by National Institutes of Health grants PO1 CA 114046, P01 CA 025874, R01 CA 047159, and P50 CA174523, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Vienna Hans Mayr-Fund, and the Vienna Science and Technology Fund LS11- 045. Core support for The Wistar Institute was provided by the Cancer Center Support Grant P30 CA010815.
Co-authors of this study from The Wistar Institute include: Gao Zhang, Mizuho Fukunaga-Kalabis, Michela Perego, Clemens Krepler, Denitsa Hristova, Qin Liu, Rufus Hards, Lawrence Wu, Manashree Damle, Courtney Ellingsworth, Leon Grinman, Harry Choi, Brian J. Gavin, Laura Gross, Marilda Beqiri, and Dorothee Herlyn. Other co-authors include: Xiaowei Xu, Margaret Dunagin, Arjun Raj, Nathalie Sholler, Brian J. Czerniecki, and Lynn Schuchter from the University of Pennsylvania; Christine Wagner, Kanika Garg, Johannes Griss, Margarita Maurer, Ahmad Jalili, Verena Bauer-Pohl, Marius Mayerhöfer, and Georgios Karanikas from the Medical University of Vienna, Austria; Felix Weihsengruber and Klemens Rappersberger from The Rudolfstiftung Hospital, Vienna, Austria; Jie Zhang, Tian Tian, and Zhi Wei from New Jersey Institute of Technology; Christine Hafner from Karl Landsteiner University of Health Sciences, St. Pölten, Austria; Josef Koller and Roland Lang from Paracelsus Medical University Salzburg, Austria; Courtney Hudgens, Michael Tetzlaff, Michael Davis, Guo Chen, and Jennifer Wargo from The University of Texas MD Anderson Cancer Center; Dennie Tompers Frederick and Keith Flaherty from Harvard Medical School; Richard A. Scolyer and Georgina V. Long from The University of Sidney, Australia; Keiryn Bennet from the Austrian Academy of Sciences, Vienna, Austria; Ian Watson from McGill University, Montreal, Canada; and Helmut Schaider from University of Queensland, Brisbane, Australia.